We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Insmed (INSM - Free Report) will report quarterly loss of $1.19 per share in its upcoming release, pointing to a year-over-year decline of 8.2%. It is anticipated that revenues will amount to $93.31 million, exhibiting an increase of 18% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Insmed metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Japan' stands at $24.10 million. The estimate points to a change of +50.3% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Europe and rest of world' should arrive at $5.45 million. The estimate indicates a change of +42.1% from the prior-year quarter.
The average prediction of analysts places 'Revenue- U.S.' at $64.70 million. The estimate suggests a change of +9.3% year over year.
Over the past month, Insmed shares have recorded returns of -2.7% versus the Zacks S&P 500 composite's +1.8% change. Based on its Zacks Rank #3 (Hold), INSM will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Insmed (INSM - Free Report) will report quarterly loss of $1.19 per share in its upcoming release, pointing to a year-over-year decline of 8.2%. It is anticipated that revenues will amount to $93.31 million, exhibiting an increase of 18% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Insmed metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Japan' stands at $24.10 million. The estimate points to a change of +50.3% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Europe and rest of world' should arrive at $5.45 million. The estimate indicates a change of +42.1% from the prior-year quarter.
The average prediction of analysts places 'Revenue- U.S.' at $64.70 million. The estimate suggests a change of +9.3% year over year.
View all Key Company Metrics for Insmed here>>>
Over the past month, Insmed shares have recorded returns of -2.7% versus the Zacks S&P 500 composite's +1.8% change. Based on its Zacks Rank #3 (Hold), INSM will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>